They have discontinued disclosing data regarding # of radiology/pathology/tele-radiology tests done each Quarter. So now observing test realization trends will no longer be possible. Below slide from Q1FY23 presentation is missing in the latest one
IMO, this indicates poor corporate governance. A new company like them shouldn’t be reducing transparency.
Investor presentation here.
| Subscribe To Our Free Newsletter |
